Hutchison China MediTech Limited (HCM): Price and Financial Metrics

Hutchison China MediTech Limited (HCM)

Today's Latest Price: $31.69 USD

0.63 (2.03%)

Updated Nov 27 1:00pm

Add HCM to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 115 in China

See all "A" rated Strong Buy stocks

HCM Stock Summary

  • With a price/sales ratio of 20.63, Hutchison China MediTech Ltd has a higher such ratio than 91.56% of stocks in our set.
  • With a year-over-year growth in debt of -33.83%, Hutchison China MediTech Ltd's debt growth rate surpasses only 9.34% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Hutchison China MediTech Ltd is reporting a growth rate of -1,024.56%; that's higher than only 1.95% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Hutchison China MediTech Ltd are ZNGA, GEOS, TSEM, DZSI, and IPHA.
  • HCM's SEC filings can be seen here. And to visit Hutchison China MediTech Ltd's official web site, go to

HCM Stock Price Chart Interactive Chart >

Price chart for HCM

HCM Price/Volume Stats

Current price $31.69 52-week high $34.90
Prev. close $31.06 52-week low $14.74
Day low $30.03 Volume 145,800
Day high $31.88 Avg. volume 247,637
50-day MA $31.77 Dividend yield N/A
200-day MA $26.79 Market Cap 4.23B

Hutchison China MediTech Limited (HCM) Company Bio

Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health-related consumer products primarily in China. The company was founded in 2000 and is based in Hong Kong, Hong Kong.

HCM Latest News Stream

Event/Time News Detail
Loading, please wait...

HCM Latest Social Stream

Loading social stream, please wait...

View Full HCM Social Stream

Latest HCM News From Around the Web

Below are the latest news stories about Hutchison China MediTech Ltd that investors may wish to consider to help them evaluate HCM as an investment opportunity.

Billionaire Li Ka-shing’s biotech unit hopes for new cancer drug approvals, expands sales army in China amid stock rally in London

Hutchison China MediTech (Chi-Med), whose stock has surged 70 per cent in London over the past six months, expects to receive approvals to sell its endocrine and lung cancer drugs in China by June next year, chief executive officer Christian Hogg said.The cancer drugs manufacturing and innovation unit of billionaire Li Ka-shing‘s conglomerate CK Hutchison, plans to triple the size of its marketing team over the next three years in anticipation of the green light, he added. That will take the…

South China Morning Post | October 1, 2020

Hutchison China MediTech (HCM) Presents At ESMO Virtual Congress 2020 - Slideshow

The following slide deck was published by Hutchison China MediTech Limited in conjunction with this event....

SA Transcripts on Seeking Alpha | September 24, 2020

Chi-Med launches late-stage fruquintinib study in colorectal cancer

Hutchison China MediTech (HCM) has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metastatic colorectal cancer ((CRC)) in the U.S., Europe and Japan. The first patient was dosed on September 3, 2020, in the U.S. The primary endpoint of the study is overall survival....

Seeking Alpha | September 4, 2020

Hutchison China MediTech Limited (HCM) Q2 2020 Earnings Call Transcript

Image source: The Motley Fool. Hutchison China MediTech Limited (NASDAQ: HCM)Q2 2020 Earnings CallJul 30, 2020, 8:00 a.m. ETContents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks: Mr.

Yahoo | July 31, 2020

Chi-Med Reports 2020 Interim Results and Provides Updates on Key Clinical Programs

– Strong global pipeline progress – three U.S. FDA1 Fast Track Designations; surufatinib U.S. NDA2 preparations underway; and initiation of global Phase III for fruquintinib – – Two further NDAs submitted in China – savolitinib in MET3 Exon 14 skipping mutation NSCLC4, and surufatinib in pancreatic NET5 –  – Expansion of commercial activities in oncology – Chi-Med to be responsible for medical detailing and marketing for Elunate® throughout Mainland China starting October 2020 –– Company to Host Results Call & Webcast Today at 1 p.m. BST / 8 a.m. EDT / 8 p.m. HKT –HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 30, 2020 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (Nasdaq/AIM: HCM), an innovation-driven, commercial-stage biopharmaceutical company, today announce...

Yahoo | July 30, 2020

Read More 'HCM' Stories Here

HCM Price Returns

1-mo 7.64%
3-mo -4.61%
6-mo 41.60%
1-year 31.44%
3-year -8.38%
5-year N/A
YTD 26.41%
2019 8.58%
2018 -41.43%
2017 190.49%
2016 N/A
2015 N/A

Continue Researching HCM

Want to see what other sources are saying about Hutchison China MediTech Ltd's financials and stock price? Try the links below:

Hutchison China MediTech Ltd (HCM) Stock Price | Nasdaq
Hutchison China MediTech Ltd (HCM) Stock Quote, History and News - Yahoo Finance
Hutchison China MediTech Ltd (HCM) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9036 seconds.